Amgen’s Approach to Responsible Pricing
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
- Pricing our products according to the value they deliver
- Employs flexible pricing approaches to ensure patient access
|Our Prices Take Multiple Factors Into Consideration, Including:|
Pricing our products according to the value they deliver
Benefits to Patients and Society
Benefits to the Healthcare System
Benefits to the Economy
Employs flexible pricing approaches to ensure patient access
Needs of Patients and Local Health Systems
General Market Dynamics
While governments and health insurers are the providers of health care coverage, we offer financial assistance to qualified patients who need support in affording their medicines. We also offer programs to limit out of pocket spending on medications and support compassionate use and expanded access to our investigational therapies for patients across the globe.
The sale of our medicines provides us with the investment required to fund future research and development to address serious, unmet medical need to improve upon the impact that some diseases have on society and our ability to live long, healthy lives. Over the past five years, we invested nearly $20 billion* in R&D, resulting in the approval of four novel first in class medicines, an innovative portfolio where approximately three-quarters of our clinical stage assets have first in class potential, in addition to delivering high quality and reliably supplied biosimilars.